Key statistics
On Thursday, Supernus Pharmaceuticals Inc (SUPN:NMQ) closed at 31.98, 25.17% above the 52 week low of 25.55 set on Jul 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.14 |
---|---|
High | 32.55 |
Low | 31.75 |
Bid | 13.46 |
Offer | 33.22 |
Previous close | 32.07 |
Average volume | 721.75k |
---|---|
Shares outstanding | 55.99m |
Free float | 52.45m |
P/E (TTM) | 28.96 |
Market cap | 1.79bn USD |
EPS (TTM) | 1.10 USD |
Data delayed at least 15 minutes, as of Jul 03 2025 18:00 BST.
More ▼
- Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
- Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
- Supernus Announces Paragraph IV ANDA Filings for Qelbree®
- Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
- Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals
- Supernus Announces First Quarter 2025 Financial Results
- Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
- Supernus to Participate in Two Upcoming Investor Conferences
- Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
- Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
More ▼